DEA Begins Formal Hearing on Rescheduling Marijuana to Schedule III

The Drug Enforcement Administration (DEA) has officially convened formal administrative hearings in Washington, D.C., to evaluate the Department of Health and Human Services' recommendation to move marijuana from Schedule I to Schedule III. This marks the first time in over fifty years that the federal government has formally entertained downgrading the drug's classification under the Controlled Substances Act.[1][3]

The hearings, presided over by an administrative law judge, are a required statutory step before any final rule can be issued. During these proceedings, the DEA will hear testimony from medical experts, law enforcement officials, industry representatives, and public health advocates. The judge will then compile a report and recommendation for the DEA Administrator, who holds the final authority on the scheduling decision.[3][6]

Currently, marijuana sits in Schedule I alongside heroin and LSD, a category reserved for drugs with "no currently accepted medical use and a high potential for abuse." Moving it to Schedule III would place it in the same category as ketamine, anabolic steroids, and Tylenol with codeine—acknowledging medical utility and a lower potential for abuse, though it remains a federally controlled substance.[1][5][6]

The core of the Department of Health and Human Services (HHS) recommendation rests on a comprehensive FDA review concluding that marijuana does have accepted medical uses, particularly for chronic pain, anorexia related to medical conditions, and nausea. HHS argues that the drug's safety profile, while not benign, does not warrant the draconian restrictions of Schedule I.[1][3][5]

However, the medical consensus is not absolute. The American Medical Association (AMA) submitted testimony emphasizing that while rescheduling could facilitate much-needed clinical research, raw botanical cannabis has not gone through the rigorous FDA approval process required for prescription drugs. The AMA cautioned against interpreting a Schedule III designation as a blanket endorsement of safety for recreational use.

Strong opposition is emerging from various law enforcement coalitions. Several police unions and former DEA administrators are testifying that downgrading marijuana will complicate enforcement efforts and send a dangerous signal amid an ongoing national addiction crisis. They argue that the high-potency THC products currently dominating state markets are vastly different from the marijuana studied in older clinical trials.[2]

For the multi-billion dollar state-legal cannabis industry, the hearings represent an existential financial pivot. Under current law, a provision known as Section 280E of the Internal Revenue Code prevents businesses selling Schedule I or II substances from deducting ordinary business expenses from their federal taxes.[4]

This tax code anomaly means that state-licensed dispensaries often pay effective federal tax rates exceeding 70 percent. Moving marijuana to Schedule III would immediately exempt these businesses from Section 280E, potentially injecting hundreds of millions of dollars of free cash flow back into the industry and making many currently unprofitable companies viable.[4]

A critical point of confusion among the public is the distinction between rescheduling and descheduling. Moving marijuana to Schedule III does not federally legalize the state-level recreational markets that currently operate in 24 states. Anyone manufacturing, distributing, or possessing a Schedule III drug without a federal prescription is still technically violating federal law.[1][3][6]

This means the glaring disconnect between state and federal law will persist. State-licensed dispensaries will still be selling a federally controlled substance to adults without prescriptions. However, legal experts suggest that a Schedule III designation would make it even less likely that the Department of Justice would expend resources prosecuting state-compliant businesses.[3]

For the scientific community, the shift would dismantle decades-old bureaucratic hurdles. Currently, researchers studying Schedule I drugs must obtain specialized DEA registrations, use DEA-approved safes, and source their cannabis from a limited number of federally approved growers.[5]

A Schedule III designation would allow researchers affiliated with universities and hospitals to study the drug much more freely, potentially unlocking federal grant money and accelerating clinical trials on both the therapeutic benefits and the long-term risks of high-potency THC consumption.[5]

The hearings also carry immense political weight leading into the midterm and presidential cycles. The Biden administration initiated the review process, and political strategists view the rescheduling effort as a key deliverable for younger voters and criminal justice reform advocates.[3]

The administrative hearings are expected to last several weeks, followed by a period for post-hearing briefs. The administrative law judge will then issue a recommendation, leaving the final decision to the DEA Administrator—a timeline that could easily stretch into late 2026 or early 2027.[1][6]